Boardroom Alpha
Start trial
8-K primary document
IMDX · Current Report (Form 8-K) · Filed June 17, 2026

Insight Molecular Diagnostics Inc — 8-K exhibit

ex10-1.htm
Insight Molecular Diagnostics Inc on Boardroom Alpha

 

Exhibit 10.1

 

SECOND AMENDMENT

TO THE

INSIGHT MOLECULAR DIAGNOSTICS INC.

AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN

 

This SECOND AMENDMENT TO THE INSIGHT MOLECULAR DIAGNOSTICS INC. AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN (this “Amendment”), effective as of June 11, 2026, is made and entered into by Insight Molecular Diagnostics Inc., a California corporation (the “Company”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan (as amended, the “Plan”).

 

RECITALS

 

WHEREAS, Section 13.1 of the Plan provides that the Board of Directors of the Company (the “Board”) may amend the Plan at any time and from time to time;

 

WHEREAS, the Board desires to amend the Plan to increase the aggregate number of shares of Common Stock that may be issued under the Plan as set forth in Section 4.1 of the Plan by an additional 1,750,000 shares of Common Stock; and

 

WHEREAS, the Board intends to submit this Amendment to the Company’s shareholders for their approval.

 

NOW, THEREFORE, in accordance with Section 13.1 of the Plan, the Company hereby amends the Plan as follows:

 

1. Section 4.1 of the Plan is hereby amended by deleting said section in its entirety and substituting in lieu thereof the following new Section 4.1:

 

4.1 Subject to adjustment in accordance with Section 11, a total of 5,550,000 shares of Common Stock shall be available for the grant of Awards under the Plan, of which 100% may be delivered pursuant to Incentive Stock Options. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards.

 

2. This Amendment shall be effective on the date first set forth above. In the event shareholder approval of this Amendment is not obtained within twelve (12) months of the date the Board approved this Amendment, the additional shares added to the Plan pursuant to this Amendment shall not be available for grant as Incentive Stock Options.

 

3. Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions thereof.

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer